---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104998"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T18:20:55.159638+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics Q2 net loss $11.2M, cash at $10.2M; collaboration with Chugai announced

## Summary
- Net loss of $11.2M for Q2 2025 vs $13.4M in Q2 2024; includes $3.3M stock-based compensation.
- Cash, equivalents and marketable securities fell to $10.2M as of June 30, 2025 from $27.6M at Dec 31, 2024.
- Entered research collaboration with Chugai for two undisclosed molecules; bioequivalence to subcutaneous delivery confirmed.
- Warrant inducement transaction yielded $4.3M gross proceeds; registered direct offering raised $3.0M.
- Phase 1 trial of oral GLP-1/GLP-2 agonist RT-114 for obesity expected to start H2 2025.

## SEC filing metadata
- accession: 0000950170-25-104998
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017025104998/0000950170-25-104998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017025104998/rani-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104998
- JSON: https://secwatch.observer/filing/0000950170-25-104998.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104998.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.